Inmed Pharmaceuticals Inc. · NASDAQ:INM
Inmed Pharmaceuticals — Investor Presentation (April 2026)
24 slides from Inmed Pharmaceuticals's investor presentation, April 2026
Slide 1: Corporate Presentation
Corporate Presentation April 2026 :INM www.inmedpharma.com
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements and forward-looking information within the meaning of applicable securities laws (collectively, “forward-looking statements”) including, among others, statements concerning: anticipated development activities, timelines
Slide 3: Executive Summary & Highlights
Executive Summary & Highlights InMed’s lead drug candidate, INM-901, targets neuroinflammation in Alzheimer’s. INM-901 is a proprietary, orally bioavailable, disease-modifying therapeutic that is a preferential CB1/CB2 signaling agonist that can cross the blood-brain barrier. • Additional R&D pipeli
Slide 4: Pharmaceutical Pipeline: Small Molecules Targeting CB1/CB2
Pharmaceutical Pipeline: Small Molecules Targeting CB1/CB2 SCREENING PRECLINICAL PH 1 PH 2 PH 3 INM-901 Alzheimer’s disease INM-089 Dry Age-related Macular Degeneration (AMD) INM-755 Epidermolysis bullosa (EB) OTHER R&D : INM
Slide 5: Alzheimer's Disease – A Major Medical & Societal Burden
Alzheimer’s Disease – A Major Medical & Societal Burden CURRENT TREATMENT OPTIONS DO NOT REVERSE EFFECTS What is Alzheimer’s Disease? Impact Alzheimer's is a subset of dementia that impacts • 7.2M Americans affected the part of the brain that controls thought, memory • 1 in 9 people age 65+ (11%) an
Slide 6: Evolving Perspective in the AD Community: Neuroinflammation Response
Evolving Perspective in the AD Community: Neuroinflammation Response in Alzheimer’s Disease OLD VIEW NEW VIEW Historical View • Aβ (amyloid-beta) and tau considered the primary causes of AD New Perspective • Aβ and tau are now viewed as part of a Aβ & Tau Aβ & Tau more complex disease process • AD r
Slide 7: The Key Players in Neuroinflammation: Microglia and Astrocytes
The Key Players in Neuroinflammation: Microglia and Astrocytes Microglia Astrocytes (The Sentinels) (The Support System) Protective (M2) Protective (A2) Responsible for neuroinflammation Releases anti-inflammatory resolution, phagocytosis of debris, molecules (TGF-β) and TGF-β GDNF and anti-inflamma
Slide 8: Role of CB1/CB2 Receptors in Targeting Microglia and Astrocytes
Role of CB1/CB2 Receptors in Targeting Microglia and Astrocytes Role of CB2 Receptors in Neuroinflammation – Anti-inflammatory • Immune Regulation: Highly expressed on microglia and astrocytes during CB1 and CB2 receptors inflammation, CB2 receptors are upregulated in response to injury or disease m
Slide 9: INM-901 Demonstrates Positive Impacts on AD Pathologies
INM-901 Demonstrates Positive Impacts on AD Pathologies Multiple pro-inflammatory and neurodegenerative biomarkers are elevated in AD; INM-901 demonstrated meaningful decreases in these proteins. AD INM-901 Astrocyte GFAP TNF-⍺ INFy IL-1β IL-6 CB2 NfL Microglia : INM
Slide 10: INM-901 Proof of Concept in Alzheimer's Using 5xFAD Mouse Model
INM-901 Proof of Concept in Alzheimer’s Using 5xFAD Mouse Model LONG TREATMENT DURATION AND ADVANCED DISEASE STAGE + + + 9 months old male mice 2-month-old male mice were injected twice-weekly for 7 months This study evaluates INM-901 in the 5xFAD (amyloidosis) mouse model, using a long treatment du
Slide 11: INM-901 Demonstrates Positive Trends Across all Tested Parameters in Cognitive Function
INM-901 Demonstrates Positive Trends Across all Tested Parameters in Cognitive Function, Anxiety-Related Behavior and Sensory Responsiveness 5xFAD mice spent more time in the center zone or open arms, suggesting reduced anxiety-like behavior. INM-901 treatment restored typical anxiety-like behavior
Slide 12: INM-901 Demonstrates Strong Neuroinflammatory Modulation in 5xFAD Mouse Model
INM-901 Demonstrates Strong Neuroinflammatory Modulation in 5xFAD Mouse Model Plasma Inflammatory Markers 5xFAD transgenic mice exhibited significantly elevated levels of these markers compared to wild-type mice. Treatment with INM-901 at 15 or 30 mg/kg resulted in a significant reduction in these b
Slide 13: Summary: INM-901 Impact on AD Pathology
Summary: INM-901 Impact on AD Pathology Anti-Inflammatory Action – 5xFAD Neuroprotection Robust Bioavailability Significantly reduced Significantly reduced amyloid-beta-induced cell Oral formulation achieved inflammatory biomarkers IFN-γ, anticipated therapeutic levels TNF-α, IL-1β, KC-GRO, IL-2 & N
Slide 14: Impact of Dry Age-related Macular Degeneration (AMD)
Impact of Dry Age-related Macular Degeneration (AMD) LEADING CAUSE OF VISION LOSS What is AMD? AMD Opportunity AMD is an eye disease that can blur your • Affects 19.8M Americans aged 40+ central vision, eventually leading to loss • 12.6% of the U.S. population of vision. It happens when aging causes
Slide 15: AMD Occurs When the Macula is Damaged
AMD Occurs When the Macula is Damaged Back of eye Retina Retina (Macular Area) Damaged Photoreceptor macula at the cells back of the eye Retinal Pigment Epithelium Choroid Age-related Optic Macular Nerve Degeneration Dry AMD is the most common form of AMD. In the advanced stages of dry AMD, called G
Slide 16: INM-089 Improved Retinal Pigment Epithelium Length in the AMD Model
INM-089 Improved Retinal Pigment Epithelium Length in the AMD Model INM-089 Improved Retinal Pigment Epithelium Integrity RPE65 analysis. (A) Retinal cryosections were immunostained with anti-RPE65 (red). The cryosections crossing the optic nerve were selected for the analysis and the integrity of t
Slide 17: INM-089: A Differentiated Approach to Treating Dry AMD
INM-089: A Differentiated Approach to Treating Dry AMD Ability to proactively A preferential signaling ligand protect the retinal for CB1 and CB2 ganglion cells Demonstrated promise Improved the thickness of in preserving retinal function in an INM-089 the outer nuclear layer of the retina where the
Slide 18: INM-755 Cannabinol (CBN) Cream: Phase 2 Results in Itch
INM-755 Cannabinol (CBN) Cream: Phase 2 Results in Itch Conducted in Epidermolysis bullosa patients – a severe genetic dermatological disease with chronic, severe itch as a primary symptom. Key Results: Non-Wound Itch: Data breakdown Of the 18 participants assessed, chronic itch improved by a • A po
Slide 19: Corporate
Corporate
Slide 20: Depth in Pharmaceutical R&D
Depth in Pharmaceutical R&D EXTENSIVE EXPERIENCE IN PHARMA DISCOVERY, Drug Development Eric A. Adams, MIBS Neeta Jagpal, CPA Michael Woudenberg, PEng Colin Clancy Chief Executive Officer Chief Financial Officer Chief Operating Officer VP, IR & Corp Comms 30+ years of experience 20+ years of biotech
Slide 21: Distinguished Board of Directors
Distinguished Board of Directors Andy Hull Neil Klompas, CPA, CA Eric A. Adams, MIBS Chair, Board of Directors Chair, Audit Committee Chief Executive Officer 30+ years of commercial and 30+ years of senior 30+ years of experience business development roles management in biotech, in global biopharma
Slide 22: Financial Snapshot (As of 03/30/2026)
Financial Snapshot ( As of 03/30/2026) Cash and Short-term Investments $7M(1) Shares I/O 4.2 M(2) Options 197 K Warrants and Preferred Investment Options 2.6 M(3) Fully Diluted Shares 7M Close $0.65 52-week High $7.98 52-week Low $0.65 Average Daily Volume (Trailing 50 Days) 126 K Market Cap $2.7 M(
Slide 23: Key Value Drivers – 2026 /2027
Key Value Drivers – 2026 /2027 Advance INM-901 to IND and First-in-Human Trials • Targeting pre-IND meeting with FDA in Q3 2026 • Complete outstanding IND-enabling pharmacology and toxicology studies • Submit IND in early 2027 • Initiate Phase I clinical development in 2027, creating a key value inf
Slide 24: Thank you!
Thank you! Forward Inquiries to, Colin Clancy Vice President, Investor Relations & Corporate Communications ir@inmedpharma.com +1-604-416-0999 :INM www.inmedpharma.com
InMed Pharmaceuticals — Investor Presentation (April 2026) on 6ix